Press Releases   Publications   Meeting Abstracts   Articles 05/19/11 US Patent Granted for a New Family of Heat Shock Protein 90 (Hsp90) Inhibitors for the Treatment of Cancer and Neurodegenerative Indications   04/19/10 NexGenix Pharmaceuticals to Present at 5 Conferences in April and May 2010   10/22/09 NexGenix Pharmaceuticals Awarded Phase I Grant from the National Institute of Neurological Disorders and Stroke (NINDS) Small Business Innovation Research Program (SBIR) for the Development of Novel Small Molecule Hsp90 Therapeutics to Treat Glioma. NexGenix Pharmaceuticals to Present at the 2009 Joint Meeting of the Society for Neuro-Oncology and the AANS/CNS Section on Tumors.   09/10/09 NexGenix Pharmaceuticals to Present at Two Industry Conferences: Rodman & Renshaw 11th Annual Healthcare Conference and Life Sciences Summit 2009   04/16/08 NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the Annual Meeting of the American Association for Cancer Research (AACR); Scientific Advisory Board Chairman Tyler Jacks named President-elect of AACR   02/22/08 NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference   11/01/07 NexGenix Pharmaceuticals to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference   07/13/07 NexGenix Pharmaceuticals Closes $3.9M Round of Financing   10/24/06 NexGenix Pharmaceuticals to Present at Rodman & Renshaw 8th Annual Healthcare Conference   05/23/06 NexGenix Pharmaceuticals to Present at BIO VentureForum East 2006   09/29/05 NexGenix Pharmaceuticals to Present at the Rodman and Renshaw Techvest 7th Annual Healthcare Conference Back to top